Roche’s Tecentriq had begun to show signs of reviving its hopes in the competitive PD-1/L1 market, succeeding in two Phase 3 trials in lung cancer and receiving a NICE approval.
A drug’s work is never done when it comes to snagging more indications but Roche have hit a stumbling block in metastatic colorectal cancer (mCRC), after four patient deaths in a trial.
Original Article: Roche’s immunotherapy lucky streak ends with deaths in trial